Sold as Primsol. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Trimethoprim Hydrochloride (sold as Primsol), first approved Jun 23, 1995, with 0 new uses approved and 0 published complete response letters.
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma · Merck Sharp & Dohme LLC | Phase 2 / Phase 3 | Not yet recruiting | Nov 5, 2026 |
| Zuberitamab in the First Episode of Paediatric Nephrotic SyndromeNephrotic Syndrome · Children's Hospital of Fudan University | Phase 3 | Not yet recruiting | Aug 14, 2026 |
| TMP-SMX for Non-HIV PCP: A Prospective Multicenter StudyPneumocystis Jirovecii Pneumonia in Non-HIV Patients · Second Affiliated Hospital, Zhejiang University, School of Medicine | — | Not yet recruiting | Jul 8, 2026 |
| Precision Management of Urinary Tract Symptoms in Older WomenUrinary Tract Infection (Diagnosis) · Megan Bradley | Phase 3 | Recruiting | Jul 7, 2026 |
| Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPDChronic Obstructive Pulmonary Disease (COPD) · Second Affiliated Hospital, Zhejiang University, School of Medicine | Not applicable | Not yet recruiting | Jun 24, 2026 |
| Self-Start Triage Model for Post-Botox® Lower Urinary Tract SymptomsOveractive Bladder · The Cleveland Clinic | Early phase 1 | Recruiting | Jun 15, 2026 |
| Low- vs Standard-Dose TMP-SMX for Prevention of Pneumocystis Pneumonia After Kidney TransplantationPneumocystis Jirovecii Pneumonia, Kidney Transplantation · Anhui Provincial Hospital | Phase 4 | Not yet recruiting | Jun 1, 2026 |
| Extended Oral Antibiotic Prophylaxis in Diabetic Fracture PatientsFracture Lower Leg, Diabetes · Texas Tech University Health Sciences Center, El Paso | Phase 4 | Recruiting | May 1, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA